Stock Ratings / Health Care / VSTM / earnings

RAPP (31) AMPH (72) AVLN (44) SPTX (55) ⌘ Pro Terminal →

Verastem Inc. (VSTM) Next Earnings Date & Expected ±12.5% Move

$9.66 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.61

Verastem Inc. (VSTM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.17B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VSTM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.66 (-1.78% 1D, market cap $1.17B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VSTM ranks #629 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VSTM compare to RAPP and AMPH in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RAPP (Rapport Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VSTM?

▼

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.61 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY VSTM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (44% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 84% of 52W Range • RSI-14 at 60.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.25+4.5% Next Q

Q2 (-2Q)

Grade E$8.62+16% Next Q

Q3 (-1Q)

Grade E$10.00-3.4% Next Q

Current

Grade D-$9.66-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VSTM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.21) and Max Pain ($10.14) forces dealer call-delta covering toward $11.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.21 Expected Swing

MODEL EARNINGS SETUP GAUGE

VSTM Quantitative Pre-Earnings Setup: 36/100

Trailing EPS: $4.25 • YoY Revenue Growth: 180%

Model Bullish Setup (36/100)Model Risk Weight (64/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$30.9M	-$209.5M	-$137.5M	52%
FY 2024	2024-12-31	$10.0M	-$130.6M	-$104.8M	52%
FY 2023	2023-12-31	$0	-$87.4M	-$86.5M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

✓Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.35%▲ ASCENDING CHANNEL

2026-11-02O $9.83H $9.83L $9.66C $9.66VOL 1.94M

RES: $10.35SUP: $6.99SMA50: $8.21SMA200: $6.18

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VSTM Butterfly Map → + Track VSTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #629 of 1016 ⚔️ RAPP vs VSTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VSTM vs. RAPP, AMPH, AVLN, SPTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #629 by composite RQD confidence (36/100, grade D-) and #340 by equity capitalization ($1.17B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with VSTM at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VSTM ACTIVE Verastem Inc.	D-	36/100	—	—	-35.0%	-1.78%	$1.17B	Benchmark Subject
RAPP Rapport Therapeutics Inc.	E	31/100	—	—	-22.9%	+7.60%	$1.16B	/rapp-vs-vstm →
AMPH Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	+2.28%	$1.15B	/amph-vs-vstm →
AVLN Avalyn Pharma Inc.	D	44/100	—	—	—	-0.12%	$1.14B	/avln-vs-vstm →
SPTX Seaport Therapeutics Inc.	D+	55/100	—	—	—	+3.53%	$1.13B	/sptx-vs-vstm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001526119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M ) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.9M	-$209.5M	-$137.5M	-$137.5M	$246.4M	—
FY2024 (FY)	2024-12-31	$10.0M	-$130.6M	-$104.8M	-$104.8M	$101.5M	—
FY2023 (FY)	2023-12-31	$0	-$87.4M	-$86.5M	-$86.5M	—	—

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VSTM compare to RAPP and AMPH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.66 (-1.78% on volume of 1,939,781 shares), positioning the stock +17.66% above its 50-day simple moving average ($8.21) and +56.31% above its 200-day simple moving average ($6.18). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 84.3% percentile with a 14-day RSI of 60.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.45 to $10.87).

VSTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is VSTM's next earnings date?

Based on SEC filing cadence, Verastem Inc. (VSTM)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is VSTM stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for VSTM, spanning a range between $8.45 and $10.87.

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why